Prognostic and predictive values of E-cadherin for patients of ovarian clear cell adenocarcinoma.
OBJECTIVE
The purpose of the study was to analyze negative versus positive immunoexpression of epithelial cadherin (E-cadherin) and p53 in patients with primary advanced ovarian clear cell adenocarcinoma (OCCA) and its significance in relation to clinical features, progression-free survival and overall survival (OS).


METHODS
Protein expression of E-cadherin and p53 was immunohistochemically evaluated in 61 OCCA patients with stages IIC to IV. The clinical factors studied included stage, age, CA-125, residual tumors, and chemotherapy regimens.


RESULTS
Positive p53 immunoexpression was 44.8% (26/58) of OCCAs; in contrast, E-cadherin immunoexpression was observed in 75.9% (44/58) of OCCAs. The expected 5-year OS rate of OCCA treated with paclitaxel-based chemotherapy was significantly better than non-paclitaxel-based chemotherapy (40% vs 0%, P = 0.001). The expected 5-year OS rate of OCCA patients with positive E-cadherin immunoexpression (>10%) was also significantly better than patients with negative E-cadherin immunoexpression (≤10%) (35% vs 0%, P = 0.02). The expected 5-year OS rate of those receiving paclitaxel-platinum chemotherapy was not significantly different from platinum-based chemotherapy for those with negative E-cadherin immunoexpression (P = 0.11). The expected 5-year OS rate of those receiving paclitaxel-based chemotherapy was better than non-paclitaxel-based chemotherapy for those with positive E-cadherin immunoexpression (43% vs 0%, P = 0.01). Paclitaxel-based chemotherapy and positive E-cadherin immunoexpression were 2 independent prognostic factors in OS of patients with OCCA (P = 0.01 and 0.04, respectively).


CONCLUSIONS
E-cadherin is a useful prognostic marker for OCCA patients, and paclitaxel-based chemotherapy can improve survival among patients with positive E-cadherin immunoreactivity.
Gynecologic Cancer Center, Department of Obstetrics and Gynecology, Cathay General Hospital, School of Medicine, Fu Jen Catholic University, Hsinchuang, Taipei Hsien, Taiwan.
Chih-Ming
CM
Ho
Wen-Fang
WF
Cheng
Ming-Chieh
MC
Lin
Tze-Chien
TC
Chen
Shih-Hung
SH
Huang
Fu-Shing
FS
Liu
Chan-Chao Chang
CC
Chien
Mu-Hsien
MH
Yu
Tao-Yeuan
TY
Wang
Chang-Yao
CY
Hsieh
D018262:Adenocarcinoma, Clear Cell / Q000175:diagnosis* / Q000188:drug therapy / Q000378:metabolism / Q000401:mortality; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000032:analysis / Q000378:metabolism; D015820:Cadherins / Q000378:metabolism*; D002945:Cisplatin / Q000008:administration & dosage; D005260:Female; D006801:Humans; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000175:diagnosis* / Q000188:drug therapy / Q000378:metabolism / Q000401:mortality; D017239:Paclitaxel / Q000008:administration & dosage; D011237:Predictive Value of Tests; D011379:Prognosis; D016019:Survival Analysis
D014408:Biomarkers, Tumor; D015820:Cadherins; D017239:Paclitaxel; D002945:Cisplatin